At first glance, the PsyMed Ventures portfolio can look like the contents of a particularly ambitious laboratory cupboard. There are RNA medicines intended to slip across the blood-brain barrier, CRISPR tools protecting therapeutic bacteria from viruses, focused ultrasound aimed at the brain and virtual reality built to alter a user's mental state. Add clinician-supervised artificial intelligence, ketamine formulations and precision psychiatry, and the list stops resembling a conventional sector. That is the point.
PsyMed is a San Francisco venture firm organized around a problem rather than a single technology. It backs early-stage companies trying to understand, measure or improve brain and mental health. The firm's current map includes artificial intelligence, neurotechnology and human augmentation, precision neuroscience, new therapeutic modalities, holistic medicine, neurometabolism and digital care. Those labels give the portfolio room to range from a drug platform to a wearable, provided the company can plausibly improve outcomes and grow into a venture-scale business.
This was not the map in 2020. PsyMed began much closer to psychedelic medicine, an emerging category that promised new treatments for depression, addiction and post-traumatic stress while attracting a great deal of enthusiasm and some loose thinking. Co-founders Matias Serebrinsky, Greg Kubin and Dina Burkitbayeva came to the space with different combinations of operating, investing, finance and psychology experience. The first public-facing product was not a fund. It was Business Trip, a podcast that let the team interview researchers, founders and advocates while learning in public.
The podcast was the first fund
Media gave PsyMed something a new investment firm normally has to buy or borrow: repeated access. Each episode was a structured excuse to ask an expert what mattered, show prospective founders how the partners thought and gather listeners who might later become limited partners. The team then formed an AngelList syndicate, allowing accredited investors to participate deal by deal. By early 2022, the founders told Crunchbase that the syndicate had put $15.6 million into 14 companies with more than 300 participating LPs.
That sequence - conversation, community, syndicate, fund - is PsyMed's most reusable piece of company-building logic. Publishing was not decoration added after the investment product. It helped manufacture the network that made the product possible. In 2023, PsyMed formally brought the Business Trip and fund audiences together. The newsletter now carries fund updates, market essays and podcast episodes under one roof.
“We fund and support founders elevating brain and mental health through innovative neuroscience and frontier technologies.”PsyMed Ventures' stated purpose
The institutional fund introduced a different promise. Founders were no longer only receiving a check from a crowd of interested angels. They were choosing a specialist manager that could discuss clinical evidence, scientific recruiting, regulation, follow-on financing and the quirks of a market where a technically elegant result may still fail to become useful care. LPs, meanwhile, were buying a filtered route into a field that is difficult to diligence without domain expertise.
A thesis with five doors
PsyMed's 2025 investment framework made the wider strategy explicit. The firm described five favored areas: therapeutics; precision-neuroscience platforms; therapeutic medical devices; science-first consumer health; and AI-enabled care. The categories overlap by design. A wearable may produce a clinical data asset. A diagnostic platform may help drug developers select patients. Software may become part of a regulated treatment. The fund looks for a technical wedge that can expand into a defensible company, not merely a fascinating experiment.
The bars above are a visual index, not portfolio allocation. Their varied lengths make a more useful point: each door opens onto a different risk profile. A therapeutic must survive biology, trials and years of capital needs. A device must prove safety, efficacy and usability. A clinical AI company has to fit regulated workflows and keep clinicians in control. Consumer products can move faster, but weak evidence and cheap imitation are constant hazards.
Aerska captures the drug side of the thesis. PsyMed joined a $21 million financing for the company, which is developing RNA interference medicines designed to reach the central nervous system via antibody-oligo conjugates, sometimes called brain shuttles. Early programs target genetic forms of Alzheimer's and Parkinson's disease. Ancilia Biosciences, another portfolio company, uses CRISPR's natural function as a bacterial immune system to protect live biotherapeutics from destructive viruses. Neurode approaches attention-deficit/hyperactivity disorder through a wearable neurostimulation device. Jimini Health brings the strategy back to software with clinician-in-the-loop AI built for behavioral-health providers.
Who buys what PsyMed sells?
Venture capital has two customer groups and an unusually long feedback loop. Founders want money, speed, credible introductions and help navigating the next hard decision. Limited partners want access, selection and returns. A specialist fund must persuade both groups that its narrowness is an advantage. PsyMed's scientific advisors, venture partners, podcast archive and founder programs are all evidence in that argument.
Companies, technical insight and the need for patient capital.
LP capital, specialist judgment, a public audience and a brain-health network.
The revenue model is the familiar venture arrangement: a manager pools LP commitments, invests over time and typically earns management fees plus a share of profitable exits. PsyMed has not published its fee and carry terms. The syndicate added a deal-by-deal route for accredited investors. Business Trip, the newsletter and the Future Neuro Founders Workshop appear less like separate profit centers than infrastructure - ways to source companies, test ideas, grow reputation and keep the network warm between financing rounds.
That infrastructure also explains the customer experience for founders. A brain-health startup often needs investors to understand why the next milestone is a particular biomarker result or why a manufacturing constraint matters more than this quarter's revenue. A generalist can learn the story. A specialist is supposed to arrive already conversant, then help recruit the next investor who understands it too.
The difference is breadth, carefully contained
PsyMed is not alone. Palo Santo, re.Mind, Noetic, JLS Fund, What If Ventures and a growing cast of biotech and health-tech investors pursue overlapping opportunities. Large generalist funds can offer deeper reserves and brand recognition. Corporate venture arms may bring drug-development or distribution machinery. The specialist's defense is sharper pattern recognition and better access in a field where the best opportunities do not all announce themselves as “mental health.”
PsyMed's particular difference is its willingness to cross modalities without becoming a generic health fund. The unifying test is the brain. That lets the team compare a molecule, a stimulation device and an AI care platform while maintaining a recognizable boundary. Its public voice is another distinction. Few funds have documented the evolution of their thesis as consistently, including the doubts, category maps and interviews that informed it.
There is a risk in this breadth. Neuroscience can become a flattering label pasted onto unrelated businesses. Human augmentation can drift toward science fiction. PsyMed's own writing pushes back by emphasizing human data, clinical validation, defensible technology and patient outcomes. Those filters are not guarantees. They are the discipline required to keep a broad thesis from becoming an all-purpose permission slip.
From the psychedelic moment to the neuroscience market
The firm's shift also mirrors the market. Psychedelic medicine remains part of the portfolio, but the early rush has matured into longer questions about trial design, treatment duration, reimbursement and pharmaceutical partnerships. At the same time, brain imaging, neural recording, multi-omics, machine learning and delivery technologies have improved. Drug companies have shown an appetite for neuroscience assets. PsyMed argues that the combination is moving the sector out of biotech's “graveyard” reputation.
By November 2025, the firm said it was investing from Fund II, had made three investments and ranked Fund I in the top decile for its vintage. That performance description is PsyMed's own and should be read as such. The more concrete development is the second fund's public filing: a $25 million offering, with $9.975 million sold at the time of the June 2025 filing. It is enough capital to remain early and selective, not enough to win by brute force.
In 2026, PsyMed's editorial output moved even further into frontier neuroscience: whole-brain emulation, brain organoids, digital addiction and a broad “century of the brain” market thesis. The topics sound futuristic, but the firm's portfolio discipline is most convincing when it stays mundane - measurable signals, credible teams, practical clinical paths and a business model attached to the science.
That leaves PsyMed in a clear place in the market. It is smaller than the multistage firms that can finance a drug through late trials, broader than a psychedelics-only vehicle and more biologically oriented than the first wave of mental-health software investors. Its job is to find companies while they are still strange, translate the strangeness for capital and help the strongest ones cross into ordinary care. The brain is the complicated part. The pitch, by now, is unusually simple.